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Abstract 
Introduction: Statistical heterogeneity can increase the uncertainty of results and 
reduce the quality of evidence derived from systematic reviews. At present, it is 
uncertain what are the major factors that account for heterogeneity in meta-analyses 
of analgesic adjuncts. Therefore, the aim of this review was to identify whether 
various covariates could explain statistical heterogeneity and use this to improve 
accuracy when reporting the efficacy of analgesics.  
 
Methods: We searched for reviews using MEDLINE, EMBASE, CINAHL, AMED 
and Cochrane Database of Systematic Reviews. Firstly, we identified the existence of 
considerable statistical heterogeneity. Secondly, we conducted meta-regression 
analysis for the outcome of 24-hour morphine consumption using baseline risk and 
other covariates. Finally, we constructed a league table of analgesic adjuncts 
assuming a fixed consumption of postoperative morphine.  
 
Results: We included 344 randomized controlled trials with 28,130 participants. 91% 
of analyses showed considerable statistical heterogeneity. Baseline risk was a 
significant cause of between-study heterogeneity for acetaminophen, NSAIDS/COX-
2 inhibitors, tramadol, ketamine, alpha-2 agonists, gabapentin, pregabalin, lidocaine, 
magnesium and dexamethasone (R2 15-100%; p<0.05). There was some evidence that 
methodological limitations of the trials explained some of the residual heterogeneity. 
Type of surgery was not independently associated with analgesic efficacy. Assuming 
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a fixed baseline risk, gabapentin, acetaminophen, alpha-2 agonists and 
NSAIDS/COX-2 inhibitors were the most effective analgesics.  
 
Discussion: This is the first review to identify a major source of between-study 
heterogeneity in reviews of analgesic adjuncts. Moreover, we have utilized these 
findings to present a novel method of reporting effect estimates, which both reduces 
confounding from variable baseline risk in included trials and is able to adjust for 
other clinical and methodological confounding variables. We recommend use of these 
methods in future reviews of analgesics for postoperative pain. Other implications for 
clinical practice, primary and secondary research studies are discussed. 
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Introduction 
Meta-analyses have emerged as a useful method to summarize research findings and 
increase the statistical power of primary research studies. However, one of the major 
limitations of this form of analysis is the aggregation of trials conducted in both 
different populations and in different clinical circumstances. This is termed clinical 
heterogeneity. Such clinical heterogeneity, along with other methodological 
limitations, may give rise to statistical heterogeneity,1 which can be quantified using 
measures such as the I2 statistic.  
 
Unexplained statistical heterogeneity can increase the uncertainty surrounding effect 
estimates derived from meta-analyses and reduce the quality of evidence used to 
inform healthcare decisions.2  In addition, in the presence of statistical heterogeneity, 
effect estimates may be inaccurate and lead to erroneous conclusions on the clinical 
significance of a particular agent. Therefore, investigating causes for heterogeneity is 
essential using techniques such as meta-regression analysis.3  Baseline risk is a 
particular covariate that can help predict between-study heterogeneity in meta-
analyses. However, conventional meta-regression analyses may be biased due to 
measurement error in the covariate and regression to the mean.4,5  Therefore, 
alternative analyses such as Bayesian meta-regression are recommended.6  
 
Heterogeneity is a particular problem in meta-analyses of analgesics used to prevent 
postoperative pain.7  Indeed, a previous review has suggested that type of surgery 
should be explored in these review.7 However, even within the same type of surgical 
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procedure, pain levels can be heterogeneous. In addition, differing analgesic protocols 
can further confound the association between type of surgery and the efficacy of the 
analgesic. Previous primary research has shown that the pain level experienced by a 
participant determines analgesic efficacy, with higher pain levels resulting in higher 
absolute pain score reductions following analgesic administration.8,9 We have 
previously demonstrated that using control group morphine consumption (baseline 
risk), we were able to explain a large degree of between-study heterogeneity.10,11 
 
This finding may have important clinical implications as meta-analyses are often used 
to inform clinical decision-making. However, any one finding from a meta-analysis of 
an analgesic may be confounded by the variable baseline risk in the included trials. If 
control group morphine consumption is found to be a significant predictor of 
between-study heterogeneity, quoting regression parameter estimates from a fixed 
value of morphine consumption would allow more accurate comparisons between 
analgesic adjuncts and help better inform clinical decision-making. In addition, 
explaining heterogeneity could improve the quality of systematic review evidence as 
per the Grades of Recommendation, Assessment, Development and Evaluation Group 
(GRADE).2 With regards to clinical practice and trial conduct, more intensive use of 
analgesic adjuncts in situations where expected postoperative morphine consumption 
is high would help improve their clinical significance and may help reduce opioid 
adverse effects. 
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Therefore, the aims of this review were as follows: 1) due to the large number of 
previously published reviews on the subject, we searched for existing systematic 
reviews and performed a meta-epidemiological study of their methods for 
investigating heterogeneity and the methodological conduct in the included 
randomized controlled trials 2) we identified the existence of considerable statistical 
heterogeneity 3) we investigated heterogeneity using baseline risk and other clinical 
and methodological covariates 4) we utilized these principles to construct a league 
table of analgesic adjuncts assuming a fixed consumption of postoperative morphine 
to more accurately report efficacy and reduce confounding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  
8 
Methods 
We reported this review in accordance with the PRISMA checklist.12 We 
prospectively registered this review on the PROSPERO website using the registration 
number CRD42016039109. Due to the numerous previous systematic reviews 
published on the subject, the aim of this study was to search for previous reviews of 
postoperative analgesic agents and perform a meta-epidemiological study of these and 
a secondary analysis of the individual randomized controlled trials. We searched all 
databases from inception to May 2016: MEDLINE, EMBASE, CINAHL, AMED and 
the Cochrane Database of Systematic Reviews. We used the following search terms: 
‘postoperative AND pain’, ‘surgery’, ‘analgesi*’, ‘morphine AND consumption’, 
‘opioid AND consumption’ and we exploded the MeSH term ‘ACUTE PAIN’. We 
combined these terms with the specific generic term for the analgesic agent. We then 
limited our search to reviews and meta-analyses.  
 
We extracted the data onto an electronic database. We extracted the following data: 
study author, year of publication, type of agent, methods for investigating 
heterogeneity, postoperative opioid used and data used to calculate effect estimates.  
If results were not reported in the original meta-analysis, we extracted data from the 
original publications. In order to reduce selective reporting bias, if standard deviations 
were not reported, we estimated these from other studies in the analysis.13 We did not 
attempt to estimate means and standard deviations from medians or inter-quartile 
ranges due to the high likelihood of non-normal data.13 If results were not reported in 
the text, these were estimated from published graphs.  
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We had no language restrictions for inclusion in our review and we translated non-
English language papers. We included reviews that included the following analgesic 
agents versus placebo for postoperative pain: acetaminophen, non-steroidal anti-
inflammatory drugs (NSAIDS) and cyclooxygenase (COX) 2 inhibitors, tramadol, 
intravenous ketamine, alpha-2 agonists (clonidine and dexmedetomidine), gabapentin, 
pregabalin, nefopam, lidocaine, magnesium and dexamethasone. We aimed to identify 
reviews of prophylactic administration (defined as first dose given before the onset of 
pain or agents added to postoperative analgesic regimens, such as patient-controlled 
analgesia). We did not include reviews evaluating single dose analgesics for 
established postoperative pain or reviews in dental surgery, as these are unlikely to 
report 24-hour morphine consumption. 
 
The outcome of interest was 24-hour opioid consumption. We chose opioid 
consumption as this serves as a surrogate measure for both how painful the procedure 
was and any concurrent analgesia used. In addition, as participants within these trials 
can use variable amounts of morphine to achieve a desired level of comfort, it may be 
more appropriate than pain score data, which may be confounded by variable 
morphine use between the groups. Moreover, one of the main goals of multimodal 
analgesia is to reduce opioid consumption. We only included primary studies where 
we could extract morphine consumption data. If studies reported dosage per kilogram, 
we converted this to a 70-kilogram weight. We also used data from the day of surgery 
or postoperative day one and analysed this as 24-hour data. If alternative opioids were 
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reported, these were converted to morphine equivalents using the following 
conversion factors: oral to intravenous morphine (3:1),14  pethidine/meperidine 
(10:1),15 ketobemidone (1:1),16  tramadol (20:1),17 fentanyl (1:100),18 remifentanil 
(1:100),19 piritramide (1:0.75),20 hydromorphone (1:3),21 oral hydrocodone (2:1), 
intravenous oxycodone (1:1.5),22 oral oxycodone (2.5:1), papaveretum (1.5:1),23 
meptazinol (5:1),24 nalbuphine (1:1),25 propoxyphene (10:1),26 sublingual 
buprenorphine (1:25)27 and trimeperidine (2:1). 
 
We undertook assessment of randomized controlled trials from included reviews 
using the Cochrane risk of bias tool. For blinding to receive low risk, studies had to 
describe in enough detail study drugs and placebos that were identical or similar in 
appearance rather than simply describe the study as ‘double-blind’.28  Outcome 
assessment also needed to be blinded. Attrition bias would receive high risk if patients 
were excluded from the analysis for reasons that may influence opioid consumption, 
such as those with uncontrolled pain or potential opioid adverse effects. Studies only 
received low risk for selective outcome reporting if outcomes were pre-stated in a 
published protocol or trial registration referenced in the included study. Other bias 
included baseline characteristic imbalances which have been associated with 
influencing pain (for example gender and pre-operative pain)29 or industry 
sponsorship.30  
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Statistical Analysis 
To quantify the degree of statistical heterogeneity we used the I2 statistic, with values 
exceeding 75% as evidence of considerable heterogeneity and those exceeding 50% 
as evidence of moderate statistical heterogeneity.1 For the available data, we 
calculated the mean difference (MD) in morphine consumption (mg) with 95% 
confidence intervals (CI) using a random-effects model. In order to identify whether 
control group morphine consumption could explain the between-study heterogeneity 
we undertook meta-regression analysis.3 This analysis is similar to conventional 
regression analysis, although it involves using study-level covariates, such as the dose 
of the analgesic used in the trial as the predictor variable and the effect estimate (MD) 
as the outcome variable, with each study weighted for the precision of the results 
(lower standard errors having more weight).  
 
We performed meta-regression initially using control group morphine consumption 
(baseline risk) as a covariate based on previous findings.10 We also used the following 
clinical covariates: dose or route of drug administration, type of agent (NSAIDS 
versus COX-2 inhibitor for example), type of surgery and type of anesthesia. For type 
of surgery, where possible, we aimed to include procedure-specific evidence, if this 
was not possible we grouped procedures by specialty or anatomical location. In 
addition, we assessed whether measures of internal validity were responsible for 
statistical heterogeneity including: randomization, allocation concealment, blinding 
and attrition bias. Except for attrition bias, these covariates were only included in 
models if they exaggerated effect estimates. Control group morphine consumption 
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was initially added to the model, we then added other covariates to a multivariate 
model to adjust regression estimates for these confounding variables if they 
significantly improved the model, in a stepwise approach (p<0.1 for retention in the 
model). Due to the problems with analyzing baseline risk using conventional meta-
regression, we additionally undertook Bayesian meta-regression using Markov Chain 
Monte Carlo (MCMC) with Gibbs sampling following recently developed 
methodology that incorporates the uncertainty of the covariate estimates, which 
avoids the problems of regression to the mean.6 We present the results of regression 
parameters as the median with the associated 95% credible intervals (CrIs) of the 
estimated predictive distributions. Further details on these analyses are available from 
the authors on request.  
 
For conventional meta-regression, we used a restricted maximum likelihood, random-
effects model. We also used the Knapp-Hartung method to estimate p values for each 
covariate. We assessed linearity and heteroscedasticity from predicted versus residual 
plots and we assessed residuals for normality using histograms. We assessed outliers 
from studentized residual values and leverage using Cook’s distance (with values 
greater than one regarded as a cause for concern). We present results as the proportion 
of variation explained by the model (R2 analogue) with a corresponding p value. We 
undertook sensitivity analysis removing studies that had significant leverage on the 
model. We regarded p values for final models <0.005 as statistically significant 
following Sidak adjustment for multiple comparisons.  
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If we identified baseline risk as a significant cause of between-study heterogeneity, 
we produced a league table of analgesic adjuncts based on a fixed control group 
consumption of 50mg using Bayesian parameter estimates. We regarded a difference 
of >20mg as a large clinically significant difference, >10mg a moderate clinically 
significant difference and >5mg of small clinical significance. This analysis allows 
comparison of analgesic adjuncts when adjusted for the variable control group 
morphine consumption from the included randomized controlled trials in order to 
reduce confounding. However, we ranked agents based on the point estimate and did 
not incorporate the uncertainty around these into these ranks and therefore these 
should be interpreted with caution. Where dose or route of administration was found 
to be a significant predictor, we included results from the most effective clinical 
situation and specified this where appropriate (for adjusted conventional estimates). 
We present both Bayesian parameter estimates (median) and adjusted conventional 
estimates with 95% CIs/CrIs. We conducted all analyses using Comprehensive Meta-
analysis Version 3,31 STATA Version 1432 and WinBUGS Version 1.4.33  
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Results 
We included 344 randomized controlled trials with 28,130 participants (Table 1). We 
identified these studies from 8 narrative reviews ,34-41 25 systematic reviews42-66 and 
72 meta-analyses10-11, 67-136 (Figure 1). Of the included reviews that conducted a meta-
analysis, 78% investigated heterogeneity. In 75%, investigation of heterogeneity was 
conducted using subgroup or sensitivity analysis and only 18% conducted meta-
regression. In 32% of meta-analyses, investigation of heterogeneity was based on type 
of surgery, 35% used dose and 11% used type of anesthesia. In 31% of meta-analyses, 
heterogeneity was investigated using methodological covariates. On risk of bias 
assessment of the individual randomized controlled trials, adequate randomization 
was described in 58% of studies, adequate allocation concealment in 29%, adequate 
blinding in 50% and lack of attrition bias in 71% (Figure S1-10).10  
 
From the included randomized controlled trials, there was evidence of considerable 
statistical heterogeneity (I2 >75%) in most analyses (91%). On meta-regression 
analysis (Table 1), control group morphine consumption (baseline risk) explained 
between-study heterogeneity for acetaminophen, NSAIDS/COX-2 inhibitors, 
tramadol, ketamine, alpha-2 agonists, gabapentin, pregabalin, lidocaine, magnesium 
and dexamethasone (Figure 2). We could not analyze nefopam as we only identified 
five studies. When re-analysed using Bayesian meta-regression, control group 
morphine consumption remained a significant cause of heterogeneity and parameter 
estimates were very similar (Table 1). Mean control group consumption in each meta-
analysis varied between 26.76mg to 47.24mg (Table 1). 
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Other significant causes of between-study heterogeneity when added to the model 
(Table 2 and 3) included route of administration and allocation concealment for 
acetaminophen (R2=94%; p<0.001). Intravenous acetaminophen was more effective 
than other routes. For ketamine, the final model included blinding and allocation 
concealment, which explained the majority of the between-study heterogeneity 
(R2=56%; p<0.001). For alpha-2 agonists, the addition of attrition bias and route of 
administration significantly improved the model, with intravenous and epidural/spinal 
administration the most effective (R2=75%; p<0.001). The gabapentin model was 
improved by the addition of peri-operative dose (R2=93%; p<0.001). For pregabalin, 
the final model included allocation concealment, which significantly improved the 
model (R2=78%; p<0.001). For lidocaine, the final model included route of 
administration and attrition bias (R2=87%; p<0.001). Intravenous administration was 
more effective than subcutaneous patch. For magnesium, the addition of allocation 
concealment significantly improved the final model (R2=32%; p=0.006). We did not 
include dose, as this did not exaggerate effect estimates. Dexamethasone was the only 
analysis where type of surgery was a significant predictor. The final model included 
type of surgery and blinding (R2=100%; p<0.001), with larger morphine reductions in 
spinal and ENT surgery (although only based on single studies). However, analysis 
could not performed with type of surgery and allocation due to multicollinearity. 
 
When assuming a fixed consumption of 50mg of postoperative morphine (Figure 3), 
we observed moderate clinically significant reductions (in order of efficacy) with 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  
16 
gabapentin, acetaminophen, alpha-2 agonists, NSAIDS/COX-2 inhibitors, pregabalin, 
tramadol, magnesium and lidocaine. We observed small clinically significant 
reductions with ketamine and dexamethasone. When adjusting conventional estimates 
for confounders, gabapentin (1200mg) demonstrated a large clinically significant 
reduction and the results for magnesium adjusted for allocation concealment resulted 
in a small clinical effect (Table 3). 
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Discussion 
To the best of our knowledge, we report a novel, empirically-derived, consistent and 
large cause of between-study heterogeneity in meta-analyses of analgesic adjuncts. 
Control group morphine consumption (baseline risk) was a consistent predictor of 
between-study heterogeneity for all included meta-analyses on both conventional and 
Bayesian parameter estimates. In addition, we found evidence that methodological 
limitations explained some of the residual heterogeneity. Type of surgery did not 
appear to be an independent cause of between-study heterogeneity. Moreover, we 
have presented a method for more accurately reporting the efficacy of analgesics, 
which mitigates the variable morphine consumption from the included trials. 
Furthermore, these models are able to adjust estimates for clinical and methodological 
heterogeneity in the included studies.  
 
Recent meta-analyses have attempted to explore heterogeneity using clinical 
covariates such as dose and type of surgery.115 However, these often report a low 
proportion of variation explained when compared to our results using baseline risk. 
We derived this covariate from previous empirical studies suggesting larger 
reductions in pain scores following analgesic treatment with higher baseline pain 
scores. One study examined around 500 participants following dental extraction and 
found those with severe pain (3/3) had greater reductions in pain scores following 
treatment with ibuprofen compared to those with moderate pain (2/3).8 Another study 
found acetaminophen and codeine treatment following Caesarean section was only 
effective in those participants with severe pain (>6/10).9 Although it should be noted 
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other factors in addition to degree of pain may also influence postoperative opioid 
consumption such as access to patient-controlled analgesia, concurrent analgesic 
protocols, patient characteristics and the prescribing practices of attending medical 
professionals (which may be region dependent). 
 
A previous study of postoperative pain reviews has found widespread statistical 
heterogeneity and suggested that this should be explored based on type of surgery or 
pain scores.7 This review recommended future meta-analyses should include only 
trials from the same surgical procedures or those with close acute postoperative pain 
levels and explore this using subgroup analysis. We would argue that baseline risk is a 
more appropriate covariate than type of surgery and meta-regression a more useful 
analysis than subgroup analysis as it allows reporting of the proportion of 
heterogeneity explained by the model (R2) as well as the ability to adjust for other 
confounding variables. In our previous meta-analysis with gabapentin, morphine 
consumption varied even within procedure-specific subgroups and type of surgery 
was a small determinant of heterogeneity between studies in relation to morphine 
consumption and pain scores.10 Our results suggest that expected postoperative 
morphine consumption (as a surrogate for pain and concurrent analgesia) is a large 
determinant of heterogeneity between studies.  
 
Our results demonstrate that with baseline risk held constant, type of surgery was not 
a significant predictor of between-study heterogeneity for nearly all analyses. 
Previous groups have argued that procedure-specific evidence is necessary when 
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evaluating evidence derived from trials of analgesic agents.137 Our results suggest that 
the efficacy of analgesic agents is determined more by the degree of morphine 
consumption during the postoperative period rather than the type of surgery. Indeed, 
procedure-specific meta-analyses still suffer from considerable statistical 
heterogeneity.108 Therefore, we could find little empirical basis for conducting such 
procedure-specific reviews for analgesic adjuncts. However, we could not exclude an 
effect of type of surgery mediated via differences in baseline risk (some procedures 
having higher morphine consumption). Furthermore, we acknowledge that other 
interventions such as regional anaesthesia may have more relevance to procedure-
specific evidence. 
 
When reporting the results from analgesics using a fixed consumption of 
postoperative morphine, we found the most effective analgesics were gabapentin, 
acetaminophen, alpha-2 agonists, NSAIDS/COX-2 inhibitors, pregabalin, tramadol, 
magnesium and lidocaine, all with moderate clinically significant effects. Ketamine 
and dexamethasone had small clinically significant effects. However, these rankings 
should be interpreted with caution due to the uncertainties surrounding the point 
estimates, which may mean analgesics lower down the table are statistically 
equivalent. Furthermore, efficacy is not the only consideration when considering use 
of these agents. Adverse effects should also be considered when selecting an 
analgesic agent. Agents such acetaminophen, which have a low incidence of adverse 
events may be preferable to agents that induce peri-operative adverse effects such as 
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sedation with gabapentin, especially as the differences between these agents is 
negligible.  
 
In terms of the implications of our work for clinical practice, as meta-analyses are 
often used to inform clinical practice, reviews should present opioid reductions using 
a fixed consumption of morphine to more accurately reflect efficacy, as quoting the 
mean difference will be heavily influenced by the mean control morphine 
consumption from the included trials. In addition, indiscriminate use of analgesic 
adjuncts around the peri-operative period should be avoided. Instead, clinicians can 
use information from small audits of mean opioid consumption and the regression 
parameters in our analysis to estimate the likely mean reduction in morphine 
consumption for samples of patients in that particular clinical situation. As all agents 
are associated with adverse effects, this more targeted use of analgesic adjuncts may 
help improve clinical significance and avoid inappropriate use of multiple agents 
when expected opioid reductions are small. 
 
In terms of randomized controlled trial design, when studying analgesic agents for 
postoperative pain, trials should be conducted in surgeries where expected 
postoperative morphine consumption is anticipated to be high. For example, for 
intravenous acetaminophen, where the expected postoperative morphine consumption 
is either 70mg or 20mg in the first 24-hours postoperatively, the anticipated reduction 
in morphine would be 26mg and 6mg respectively. Relying solely on the mean 
difference (8mg) may underestimate clinical significance in the context where 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  
21 
postoperative morphine consumption is high. Furthermore, such larger reductions in 
morphine consumption may have a more pronounced effect on opioid adverse effects, 
which have additional clinical relevance. In terms of trial conduct, as with previous 
studies, we have found evidence that methodological limitations, in particular 
allocation concealment, were associated with larger reductions in morphine for many 
adjuncts.138 Given that only 29% of the included studies reported adequate allocation 
concealment, this is a particular area of internal validity future studies should aim to 
address. 
 
In terms of secondary research studies, future meta-analyses of postoperative 
analgesic agents should aim to explore heterogeneity using control group morphine 
consumption, in addition to other sources of clinical heterogeneity such as dose or 
route of administration. Such explanation of statistical heterogeneity would lead to 
higher quality evidence derived from these reviews as per GRADE.2 Estimates from 
these reviews should be reported using a fixed consumption of morphine to avoid 
confounding by the variable consumption of opioid in the included primary studies 
(using Bayesian analysis). As an extension to this, incorporating other clinical and 
methodological covariates into these regression models to adjust estimates can reduce 
further confounding. As systematic reviews are inherently observational (despite 
deriving data from randomized studies),139 more advanced and appropriate statistical 
methods are required (regression) that allows more accurate prediction than using 
mean differences, while having the additional advantage of controlling for known 
confounders. For these reasons, future reviews of postoperative analgesics should 
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avoid univariate subgroup analyses (due to confounding) and move towards 
multivariate regression models, which include control group morphine consumption 
(as is common practice in observational primary research studies). 
 
There are several limitations with this review. Firstly, meta-regression analysis should 
be regarded as observational despite deriving data from randomized studies. Such 
analyses are prone to both residual confounding and aggregation bias (as results are 
based on aggregated study estimates rather than from individual patients). For this 
reason, our implications for clinical practice focus on aggregated patient outcomes 
(from audits) rather than applying these to individual patients. Secondly, we cannot 
rule out type I errors in our analyses. Although conventional to set a lower level of 
significance to covariate adjustment in regression models (p<0.1), this may also 
increase false positive results. Thirdly, although our models can adjust for 
confounding variables, our analyses are limited to published primary studies and are 
therefore still susceptible to publication bias. Although identification of imprecise 
study effects is possible in systematic reviews, it is impossible to know if this is 
secondary to true publication bias and therefore this limits our findings. Finally, as we 
generally derived our studies from reviews of active versus placebo groups, we were 
unable to perform network meta-analysis, which may be a more appropriate method 
to directly compare analgesics in future reviews. 
 
In conclusion, we have identified widespread, considerable statistical heterogeneity in 
meta-analyses of analgesic adjuncts. Moreover, we have demonstrated for the first 
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time, an empirically-derived, consistent covariate responsible for a large proportion of 
between-study heterogeneity in meta-analyses of analgesics for postoperative pain. 
Extending this principle, we have presented methods for more accurate reporting of 
the efficacy of analgesics that can adjust for other clinical and methodological 
covariates. Despite the limitations of our analysis, we recommend use of these 
principles in clinical practice, primary and secondary research studies. 
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Figure Legends 
 
Figure 1: PRISMA flowchart of included reviews and randomized controlled trials. 
 
Figure 2: Meta-regression plot for included analgesics. Plots are from top left to 
bottom right: acetaminophen, NSAIDS/COX-2 inhibitors, ketamine, alpha-2 agonists, 
gabapentin, pregabalin, lidocaine, magnesium and dexamthasone. X axis is baseline 
risk (mg of control group morphine consumption) and Y axis is mean difference in 
morphine consumption (mg). 
 
Figure 3: Bar chart of reductions in 24-hour morphine consumption (y axis) for each 
analgesic agent (in order of efficacy). Figures are derived from Bayesian parameter 
estimates (medians).  
 
Figure S1: Risk of bias for acetaminophen. 
 
Figure S2: Risk of bias for NSAIDS/COX-2 inhibitors. 
 
Figure S3: Risk of bias for tramadol. 
 
Figure S4: Risk of bias for ketamine. 
 
Figure S5: Risk of bias for alpha-2 agonists. 
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Figure S6: Risk of bias for pregabalin. 
 
Figure S7: Risk of bias for nefopam. 
  
Figure S8: Risk of bias for lidocaine. 
 
Figure S9: Risk of bias for magnesium. 
 
Figure S10: Risk of bias for dexamethasone.
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 Analgesic 
Studies 
(participants) 
I2 
R2 control 
morphine (p 
value) 
Intercept 
Beta coefficient 
and (95% CIs) 
Bayesian 
Intercept 
Bayesian beta 
coefficient 
(median) and 
(95% CrIs) 
Mean control 
group morphine 
consumption in 
included trials 
Acetaminophen 25 (1812) 99% 
R2=79%; 
p<0.001 
0.84 
-0.39 (-0.49 to -
0.29) 
0.77 
-0.38 (-0.48 to -
0.28) 
 
27.97mg 
NSAIDS/COX-2 
inhibitors 
86 (6937) 92% 
R2=81%; 
p<0.001 
2.42 
-0.35 (-0.41 to -
0.30) 
2.56 
-0.36 (-0.41 to -
0.30) 
42.71mg 
Tramadol 11 (889) 90% R2=48%; p=0.03 2.93 
-0.30 (-0.56 to -
0.05) 
2.96 
-0.30 (-0.55 to -
0.03) 
 
41.58mg 
Ketamine 62 (4309) 95% 
R2=29%; 
p<0.001 
-1.05 
-0.18 (-0.25 to -
0.10) 
-1.01 
-0.18 (-0.24 to -
0.10) 
 
47.24mg 
Alpha-2 agonists 33 (1930) 96% R2=66%; -0.52 -0.34 (-0.47 to - -0.95 -0.32 (-0.44 to -  
Table 1 Click here to download Table Table 1.docx 
p<0.001 0.21) 0.19) 38.2mg 
Gabapentin 67 (5082) 97% 
R2=92%; 
p<0.001 
1.12 
-0.39 (-0.44 to -
0.34) 
1.11 
-0.39 (-0.43 to -
0.35) 
32.75mg 
Pregabalin 34 (3201) 94% 
R2=58%; 
p<0.001 
-2.62 
-0.21 (-0.30 to -
0.12) 
-2.91 
-0.20 (-0.28 to -
0.11) 
 
31.97mg 
Nefopam 5 (394) 38% N/A N/A N/A N/A N/A N/A 
Lidocaine 22 (1319) 80% 
R2=62%; 
p<0.001 
-0.25 
-0.20 (-0.31 to -
0.09) 
-0.29 
-0.20 (-0.30 to -
0.08) 
 
31.35mg 
Magnesium 22 (1194) 90% R2=15%; p=0.02 -1.74 
-0.17 (-0.31 to -
0.03) 
-1.35 
-0.19 (-0.34 to -
0.04) 
 
30.72mg 
Dexamethasone 16 (2163) 88% 
R2=100%; 
p<0.001 
0.69 
-0.19 (-0.23 to -
0.14) 
0.86 
-0.18 (-0.24 to -
0.12) 
 
26.76mg 
 
Table 1: Meta-regression estimates for each analgesic adjunct. Asterisk denotes statistical significance (p<0.1). CI=confidence interval; 
CrIs=credible intervals; I2=measure of variability in results due to between-study differences compared to sampling variance; N/A=not 
applicable; R2=proportion of between-study variance explained by model.  
 
 Analgesic Type of surgery 
Type of 
anesthesia 
Type of regimen, 
dose or route Random Allocation 
 
 
Blinding Attrition 
Acetaminophen 
R2=4%; p=0.22 (CABG, 
ENT, cholecystectomy, 
C-section, orthopedic, 
hysterectomy and spinal 
surgery) 
R2=0%; p=0.95 
(GA, SA and 
mixed) 
R2=6%; p=0.05 (IV, 
PO and PR) 
R2=0%; 
p=0.80 
R2=4%; 
p=0.09 (low 
and unclear 
risk) 
 
 
 
R2=2%; 
p=0.21 
R2=0%; 
p=0.97 
NSAIDS/COX-2 
inhibitors 
R2=4%; p=0.31 
(abdominal, mixed 
arthroplasty, C-section, 
CABG, cholecystectomy, 
hip arthroplasty, 
R2=3%; p=0.18 
(NR, GA, 
GA/LA, GA/SA 
and GA/SA/EA)  
R2 =2%; p=0.83 
(NSAID and COX-
2) and R2=1%; 
p=0.89 (IM, IN, IV, 
PO and PR) 
R2=2%; 
p=0.47 
R2=2%; 
p=0.31 
 
 
 
 
 
R2=1%; 
p=0.84 
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hysterectomy, knee 
arthroplasty, mixed 
surgeries, orthopedic, 
spinal surgery, 
thoracotomy, thyroid and 
tonsillectomy) 
 
 
 
 
R2=3%; 
p=0.17 
Tramadol 
R2=0%; p=0.99 
(abdominal, C-section, 
CABG, knee arthroplasty 
and TURP) 
R2=1%; p=0.47 
(GA and SA) 
R2=0%; p=0.59 (IV 
and spinal) and 
R2=6%; p=0.25 
(dose) 
R2=0%; 
p=0.80 
R2=10%; 
p=0.22 
 
 
R2=0%; 
p=0.87 
R2=0%; 
p=0.63 
Ketamine 
R2=0%; p=0.45 
(abdominal, arthroplasty, 
arthroscopy, C-section, 
cholecystectomy, ENT, 
R2=0%; p=0.44 
(GA, GA/EA, 
GA/RA, LA, 
mixed and SA) 
R2=0%; p=0.86 
(total 24-hour dose 
in milligrams) 
R2=4%; 
p=0.09 (low, 
unclear and 
high risk) 
R2=4%; 
p=0.1 (low, 
unclear and 
high risk) 
 
 
 
R2=17%; 
R2=0%; 
p=0.45 
gynecology, 
hysterectomy, mixed 
surgeries, orthopedic, 
spinal surgery and 
thoracotomy) 
p<0.001 
(low, 
unclear 
and high 
risk) 
Alpha-2 agonists 
R2=0%; p=0.87 
(abdominal, arthroplasty, 
C-section, CABG, ENT, 
gynecology, 
hysterectomy, spinal 
surgery and 
cholecystectomy) 
R2=0%; p=0.53 
(EA, GA, NR, 
GA/EA, GA/SA 
and SA) 
R2=1%; p=0.12 
(dexmedetomidine 
and clonidine) and 
R2=34%; p=0.07 
(IV, IV/SC, PO/SC, 
PO and 
spinal/epidural) 
R2=0%; 
p=0.87 
R2=0%; 
p=0.87 
 
 
 
 
R2=0%; 
p=0.60 R2=0%; 
p=0.34 
Gabapentin 
R2=0%; p=0.36 
(abdominal, 
R2=1%; p=0.08 
(GA, SA, GA/RA 
R2=1%; p=0.008 
(peri-operative dose 
R2=0%; 
p=0.99 
R2=0%; 
p=0.84 
 
 
R2=1%; 
p=0.12 
hysterectomy, breast, 
CABG, cholecystectomy, 
C-section, arthroplasty, 
arthroscopy, nasal, 
neurosurgery, orthopedic, 
plastic surgery, spinal 
surgery, thoracotomy, 
thyroid and 
tonsillectomy) 
and GA/EA) in milligrams)  
 
 
 
 
 
 
R2=1%; 
p=0.15 
Pregabalin 
R2=0%; p=0.89 
(abdominal, arthroscopy, 
breast, cardiac surgery, 
cholecystectomy, ENT, 
hysterectomy, 
laparoscopic abdominal, 
mixed surgeries, 
orthopedic, spinal 
surgery and arthroplasty) 
 
 
 
 
 
 
R2=0%; p=0.58 
(RA, SA/RA, SA 
and GA) 
R2=0%; p=0.84 
(peri-operative dose 
in milligrams) 
R2=5% 
p=0.11 (low 
and unclear 
risk) 
R2=20%; 
p=0.004 (low 
and unclear 
risk) 
 
 
 
 
 
 
 
R2=9%; 
p=0.01 
(low, 
unclear 
and high 
risk) 
R2=0%; 
p=0.70 
Nefopam N/A N/A N/A N/A N/A N/A N/A 
Lidocaine 
R2=0%; p=0.33 
(abdominal, breast, 
cholecystectomy, ENT 
and spinal surgery) 
N/A (only GA 
subgroup) 
R2=8%; p=0.99 (24-
hour dose in 
milligrams) and 
R2=18%; p=0.03 
(intravenous versus 
patch)  
R2=21%; 
p=0.06 (did 
not 
exaggerate 
effect 
estimate) 
R2=0%; 
p=0.58 
R2=4% 
p=0.18 R2=13%; 
p=0.05 
(low and 
unclear 
risk) 
Magnesium 
R2=0%; p=0.69 
(abdominal, cardiac 
surgery, 
cholecystectomy, 
hysterectomy, mixed 
surgeries, orthopedic and 
spinal surgeries) 
R2=0%; p=0.33 
(GA and SA) 
R2=17%; p=0.02 
(total 24-hour dose, 
did not exaggerate 
effect estimate) 
R2=10%; 
p=0.06 (low 
and unclear 
risk, did not 
exaggerate 
effect 
estimate) 
R2=17%; 
p=0.02 (low 
and unclear 
risk) 
 
 
 
 
 
 
R2=0%; 
p=0.87 
R2=0%; 
p=0.97 
 Table 2: Results from meta-regression analyses for the covariates below when added to the model with control group morphine consumption. 
Each covariate is reported with the R2 analogue change (%) and the p value for the change in model. Categories for each covariate are presented 
in parentheses. Risk of bias elements are classified according to the Cochrane risk of bias tool. Statistically significant results (p<0.1) are 
highlighted in bold. CABG= coronary artery bypass graft; ENT= ear, nose and throat; EA= epidural anesthesia; GA=general anesthesia; IM= 
intra-muscular; IN= intra-nasal; IV= intravenous; LA= local anesthesia; N/A= not applicable; NR=not reported; prostate; PO= oral; PR= 
rectal; RA= regional anesthesia; SA= spinal anesthesia; TURP= trans-urethral resection of prostate. 
 
Dexamethasone 
R2=0%; p=0.06 
(abdominal, 
cholecystectomy, ENT, 
hysterectomy, mixed 
surgeries, orthopaedic 
and spinal surgery) 
R2=0%; p=0.63 
(GA and SA) 
R2=0%; p=0.12 
(dose in milligrams) 
R2=0%; 
p=0.1 (low, 
unclear and 
high risk) 
R2=0%; 
p=0.18  
R2=0%; 
p=0.84 
R2=0%; 
p=0.67 
 Analgesic adjunct  
 
Mean difference on meta-analysis 
(95% CIs) 
Reduction in 24-hour  
morphine (adjusted) 
 
Reductions in 24-hour morphine 
(Bayesian; median with 95% CrIs) 
Gabapentin 
 
-8.6mg (-9.73mg to -7.46mg) 
 
-20.07mg (dose; 1200mg) -18.49mg (-19.90mg to -17.07mg) 
Acetaminophen -8.18mg (-10.57mg to -6.73mg) 
-17.96mg (administration; 
intravenous and allocation) 
 
-18.39mg (-21.54mg to -15.02mg) 
 
Alpha-2 agonists 
-10.7mg (-12.38mg to -9.01mg) 
-18.39mg (administration; 
intravenous and attrition) 
 
-16.94mg (-20.09mg to -13.57mg) 
NSAIDS/COX-2 -11.09mg (-12.73mg to -9.45mg) -15.31mg (none) -15.20mg (-16.54mg to -13.81mg) 
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 Pregabalin -8.18mg (-9.6mg to -6.76mg) 
-11.36mg (allocation) 
 
-12.75mg (-15.23mg to -10.11mg) 
Tramadol -8.48mg (-11.88mg to -4.89mg) 
-12.17mg (none) 
 
-11.99mg (-16.21mg to -7.28mg) 
Magnesium -6.77mg (-8.39mg to -5.15mg) 
-3.91mg (allocation) 
 
-10.60mg (-14.19mg to -7.10mg) 
Lidocaine -5.04mg (-7.42mg to -2.66mg) 
-9.15mg (administration; intravenous 
and attrition) 
 
-10.09mg (-13.49mg to -6.36mg) 
Ketamine -8.13mg (-10.23mg to -6.03mg) 
-7.75mg (allocation and blinding) 
 
-9.76mg (-12.15mg to -7.33mg) 
Dexamethasone -4.23mg (-5.79mg to -2.67mg) 
-5.18mg (type of surgery and 
blinding) 
-8.07mg (-9.79mg to -6.04mg) 
Nefopam -14.75mg (-19.34mg to -10.17mg) N/A N/A 
 
Table 3: League table of analgesic adjuncts assuming a 50mg consumption of morphine in the control group. Random-effects mean difference, 
adjusted and Bayesian meta-regression parameter estimates are presented. For adjusted models, covariates are listed in parentheses. We ranked 
analgesics according to point Bayesian estimates. CIs=confidence intervals; CrIs=credible intervals; mg=milligrams; N/A=not applicable. 
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